Tella Incorporation operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tella Incorporation with three other
companies in this sector in JAPAN :
BrightPath Biotherapeutics Co Ltd
sales of 155.81 million Japanese Yen [US$1.45 million]
(275.82 million Japanese Yen [US$2.57 million]
of which 58%
was Cell Sheet Regenerative Medicine Busines), and
Medrx Co Ltd
(169.86 million Japanese Yen [US$1.58 million]
of which 100%
was Software Development).
Tella Incorporation reported sales of ¥202.18 million (US$1.88 million)
December of 2019.
decrease of 60.8%
versus 2018, when the company's sales were ¥516.21 million.
Contributing to the drop in overall sales was the 55.6% decline
in Cell Therapy Support Business, from ¥79.02 million to ¥35.10 million.
There were also decreases in sales in
Cell Therapy Technology Development Busi (down 54.5% to ¥167.08 million)